Aralez Pharmaceuticals Inc. Form SC 13G/A February 14, 2017

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1) *

Aralez Pharmaceuticals, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

03852X100

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

(Page 1 of 13 Pages)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Mgm	t. L.P.	
2.	-	ROPRIATE BOX IF A MEMBER OF A	(a) o (b) ý
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		5,372,884 (1)	
REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER	
PERSON WITH		0	
	8.	SHARED DISPOSITIVE POWER	
		5,372,884 (1)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWN	ED BY EACH REPORTING
	5,372,884 (1)		
10.	CHECK BOX IF T EXCLUDES CER	ΉΕ AGGREGATE AMOUNT IN ROW (9) ΓΑΙΝ SHARES*	0
11.	PERCENT OF	CLASS REPRESENTED BY AMOU	UNT IN ROW 9
	7.68%		
12.	TYPE OF REP	ORTING PERSON*	
	PN		

Page 2 of 13

⁽¹⁾ Comprised of an aggregate of 844,583 common shares and 4,528,301 common shares underlying convertible notes held by Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Mgmt, L.P. is the general partner. The provisions of the convertible notes beneficially owned by the reporting person restrict the

Edgar Filing: Aralez Pharmaceuticals Inc. - Form SC 13G/A

conversion of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Mana	gement Company, L.P.	
2.	CHECK THE APP GROUP*	ROPRIATE BOX IF A MEMBER OF A	(a) o (b) ý
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		10,701,185 (2)	
REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER	
		0	
	8.	SHARED DISPOSITIVE POWER	
		10,701,185 (2)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWN	ED BY EACH REPORTING
	10,701,185 (2)		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) O EXCLUDES CERTAIN SHARES*		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	9.985%		
12.	TYPE OF REPO	ORTING PERSON*	
	PN		

Page 3 of 13

⁽²⁾ Comprised of an aggregate of 1,644,583 common shares and 9,056,602 common shares underlying convertible notes held by Deerfield Private Design Fund III, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Management Company, L.P. is the investment advisor. The provisions of the

Edgar Filing: Aralez Pharmaceuticals Inc. - Form SC 13G/A

convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Mgm	t III, L.P.	
2.	-	PROPRIATE BOX IF A MEMBER OF A	(a) o (b) ý
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		5,328,301 (3)	
REPORTING	7.	SOLE DISPOSITIVE POWER	
PERSON WITH		0	
	8.	SHARED DISPOSITIVE POWER	
		5,328,301 (3)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWN	ED BY EACH REPORTING
	5,328,301 (3)		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) O EXCLUDES CERTAIN SHARES*		
11.	PERCENT OF	CLASS REPRESENTED BY AMO	UNT IN ROW 9
	7.62% (3)		
12.	TYPE OF REP	ORTING PERSON*	
	PN		

Page 4 of 13

⁽³⁾ Comprised of an aggregate of 800,000 common shares and 4,528,301 common shares underlying convertible notes held by Deerfield Private Design Fund III, L.P., of which Deerfield Mgmt III, L.P. is the general partner. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of such

securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Privat	te Design Fund III, L.P.	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*(a) o (b) ý		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		5,328,301 (4)	
REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER	
		0	
	8.	SHARED DISPOSITIVE POWER	
		5,328,301 (4)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWNE	ED BY EACH REPORTING
	5,328,301 (4)		
10.	CHECK BOX IF T EXCLUDES CERT	HE AGGREGATE AMOUNT IN ROW (9) ΓΑΙΝ SHARES*	0
11.	PERCENT OF	CLASS REPRESENTED BY AMOU	JNT IN ROW 9
	7.62%		
12.	TYPE OF REPO	ORTING PERSON*	
	PN		

Page 5 of 13

⁽⁴⁾ Comprised of an aggregate of 800,000 common shares and 4,528,301 common shares underlying convertible notes. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by

the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield Intern	national Master Fund, L.P.		
2.	CHECK THE APP GROUP*	PROPRIATE BOX IF A MEMBER OF A	(a) o (b) ý	
3.	SEC USE ONL	SEC USE ONLY		
4.	CITIZENSHIP	CITIZENSHIP OR PLACE OF ORGANIZATION		
	British Virgin l	slands		
	5.	SOLE VOTING POWER		
NUMBER OF		0		
SHARES BENEFICIALLY	у ^{6.}	SHARED VOTING POWER		
OWNED BY EACH		3,008,815 (5)		
REPORTING PERSON WITH	7. 1	SOLE DISPOSITIVE POWER		
	•	0		
	8.	SHARED DISPOSITIVE POWER		
		3,008,815 (5)		
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWN	ED BY EACH REPORTING	
	3,008,815 (5)			
10.	CHECK BOX IF T EXCLUDES CER	THE AGGREGATE AMOUNT IN ROW (9) TAIN SHARES*	0	
11.	PERCENT OF	CLASS REPRESENTED BY AMO	UNT IN ROW 9	
	4.43%			
12.	TYPE OF REP	ORTING PERSON*		
	PN			

Page 6 of 13

⁽⁵⁾ Comprised of an aggregate of 472,966 common shares and 2,535,849 common shares underlying convertible notes. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by

the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	Deerfield Partne	ers, L.P.	
2.	CHECK THE APP GROUP*	ROPRIATE BOX IF A MEMBER OF A	(a) o (b) ý
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Delaware		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		2,364,069 (6)	
REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER	
		0	
	8.	SHARED DISPOSITIVE POWER	
		2,364,069 (6)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWNE	D BY EACH REPORTING
	2,364,069 (6)		
10.	CHECK BOX IF T EXCLUDES CERT	HE AGGREGATE AMOUNT IN ROW (9) ΓΑΙΝ SHARES*	0
11.	PERCENT OF	CLASS REPRESENTED BY AMOU	NT IN ROW 9
	3.51%		
12.	TYPE OF REPO	ORTING PERSON*	
	PN		

Page 7 of 13

⁽⁶⁾ Comprised of an aggregate of 371,617 common shares and 1,992,452 common shares underlying convertible notes. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by

the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
	James E. Flynn		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A(a) oGROUP*(b) ý		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION		
	United States		
	5.	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	6.	SHARED VOTING POWER	
OWNED BY EACH		10,701,185 (7)	
REPORTING PERSON WITH	7.	SOLE DISPOSITIVE POWER	
		0	
	8.	SHARED DISPOSITIVE POWER	
		10,701,185 (7)	
9.	AGGREGATE PERSON	AMOUNT BENEFICIALLY OWN	ED BY EACH REPORTING
	10,701,185 (7)		
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) O EXCLUDES CERTAIN SHARES*		
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	9.985%		
12.	TYPE OF REPO	ORTING PERSON*	
	IN		

Page 8 of 13

⁽⁷⁾ Comprised of an aggregate of 1,644,583 common shares and 9,056,602 common shares underlying convertible notes held by Deerfield Private Design Fund III, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion

of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities with which such holder would constitute a Section 13(d) "group" would exceed 9.985% of the total number of shares of the Issuer then outstanding (the "Ownership Cap"). Accordingly, notwithstanding the number of shares reported, the reporting person disclaims beneficial ownership of the common shares issuable upon conversion of such convertible notes to the extent that upon such conversion the number of shares beneficially owned by all reporting persons hereunder, in the aggregate, would exceed the Ownership Cap.

CUSIP No. 03852X100

Item 1(a).	Name of Issuer:
	Aralez Pharmaceuticals, Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices:
	7100 West Credit Avenue, Suite 101 Mississauga, Ontario Canada L5N 0E4
Item 2(a).	Name of Person Filing:
	James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield International Master Fund, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P.
Item 2(b).	Address of Principal Business Office, or if None, Residence:
	James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield International Master Fund, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017
Item 2(c).	Citizenship:
	Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P Delaware limited partnerships;
	Deerfield International Master Fund, L.P British Virgin Islands limited partnerships;
	James E. Flynn – United States citizen
Item 2(d).	Title of Class of Securities:
	Common Shares
Item 2(e).	CUSIP Number:

Page 9 of 13

Edgar Filing: Aralez Pharmaceuticals Inc. - Form SC 13G/A

03852X100

- Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
- (a) o Broker or dealer registered under Section 15 of the Exchange Act.
- (b) o Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) o Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) o Investment company registered under Section 8 of the Investment Company Act.
- (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

CUSIP No. 03852X100

(g)	0	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h)	0	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
(i)	0	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)	0	A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k)	0	Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
If filing as a	noi	n-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned**:

Deerfield Mgmt, L.P. - 5,372,884 shares Deerfield Mgmt III, L.P. - 5,328,301 shares Deerfield Management Company, L.P. - 10,701,185 shares Deerfield Partners, L.P. - 2,364,069 shares Deerfield International Master Fund, L.P. - 3,008,815 shares Deerfield Private Design Fund III, L.P. - 5,328,301 shares James E. Flynn - 10,701,185 shares

(b) Percent of class**:

Deerfield Mgmt, L.P. – 7.68% Deerfield Mgmt III, L.P. – 7.62% Deerfield Management Company, L.P. – 9.985% Deerfield Partners, L.P. – 3.51% Deerfield International Master Fund, L.P. – 4.43% Deerfield Private Design Fund III, L.P. – 7.62% James E. Flynn – 9.985%

(c) Number of shares as to which such person has**:

(i)	Sole power to vote or to direct the vote: All Reporting Persons - 0
(ii)	Shared power to vote or to direct the vote: Deerfield Mgmt, L.P 5,372,884
	Deerfield Mgmt III, L.P. – 5,328,301
	Deerfield Management Company, L.P.

10,701,185
Deerfield Partners, L.P. - 2,364,069
Deerfield International Master Fund,
L.P. - 3,008,815
Deerfield Private Design Fund III, L.P. - 5,328,301
James E. Flynn - 10,701,185

CUSIP No. 03852X100

Page 11 of 13

(iii)Sole power to dispose or to direct the disposition of:	All Reporting Persons - 0
(iv) Shared power to dispose or to direct the disposition of:	Deerfield Mgmt, L.P 5,372,884 Deerfield Mgmt III, L.P 5,328,301 Deerfield Management Company, L.P. - 10,701,185 Deerfield Partners, L.P 2,364,069 Deerfield International Master Fund, L.P 3,008,815 Deerfield Private Design Fund III, L.P 5,328,301 James E. Flynn - 10,701,185

**See footnotes on cover pages which are incorporated by reference herein.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following o.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by theParent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an

Edgar Filing: Aralez Pharmaceuticals Inc. - Form SC 13G/A

exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9.

Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

CUSIP No. 03852X100

Page 12 of 13

Item 10.

Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

CUSIP No. 03852X100

Page 13 of 13

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P., General Partner By: J.E. Flynn Capital III, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD INTERNATIONAL MASTER FUND, L.P. By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P. By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

Date: February 14, 2017

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.

Exhibit A

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Shares of Aralez Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P., General Partner By: J.E. Flynn Capital III, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD INTERNATIONAL MASTER FUND, L.P. By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P. By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a "group" with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.